Skip to main content
SpringerLink
Log in

Using Urinary Biomarkers in Urothelial Carcinoma of the Bladder and Upper Tracts

  • Chapter
  • First Online:
Bladder Cancer

  • 1033 Accesses

Abstract

Bladder cancer is the most expensive cancer to manage yet available diagnostic tools continue to harbor many limitations. In fact, the gold standard tool in bladder cancer diagnosis and surveillance is cystoscopy, which is inconvenient, invasive, and expensive. To date, urinary biomarkers are not used routinely in the evaluation and surveillance of bladder cancer, despite the expanding number of available tests. The main limitation to their use is the lack of well-defined clinical benefit. A useful biomarker test needs to be accurate, easy, fast, cheap, and safe, but on top of all this has a clinical validity proven by a properly designed clinical trial. In this chapter, we discuss the available urinary biomarkers, the rationale for their use, their test characteristics, the possible clinical scenarios where they can be used, and the future directions for design of clinical trials to establish their clinical benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

    Article  PubMed  Google Scholar 

  2. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–9.

    Article  PubMed  Google Scholar 

  3. Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447–61.

    Article  PubMed  Google Scholar 

  4. Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784–95.

    Article  PubMed  Google Scholar 

  5. Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guerin. Eur Urol. 2016;69(1):60–9.

    Article  PubMed  Google Scholar 

  6. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–5; discussion 75–7.

    Article  PubMed  Google Scholar 

  7. Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462–72.

    Article  PubMed  Google Scholar 

  8. Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007;178(1):68–73; discussion.

    Article  PubMed  Google Scholar 

  9. Cumberbatch MGK, Foerster B, Catto JWF, Kamat AM, Kassouf W, Jubber I, et al. Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2018;73(6):925–33.

    Article  PubMed  Google Scholar 

  10. Naselli A, Hurle R, Paparella S, Buffi NM, Lughezzani G, Lista G, et al. Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Focus. 2018;4(4):558–67.

    Article  PubMed  Google Scholar 

  11. Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, et al. Hexaminolevulinate- guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010;184(5):1907–13.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Dragoescu O, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64(5):846–54.

    Article  PubMed  Google Scholar 

  13. Kim SB, Yoon SG, Tae J, Kim JY, Shim JS, Kang SG, et al. Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: prospective, randomized comparison with white light cystoscopy. Investig Clin Urol. 2018;59(2):98–105.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Dalgaard LP, Zare R, Gaya JM, Redorta JP, Roumiguie M, Filleron T, et al. Prospective evaluation of the performances of narrow-band imaging flexible videoscopy relative to white-light imaging flexible videoscopy, in patients scheduled for transurethral resection of a primary NMIBC. World J Urol. 2019;37(8):1615–21.

    Article  CAS  PubMed  Google Scholar 

  15. Daneshmand S, Patel S, Lotan Y, Pohar K, Trabulsi E, Woods M, et al. Efficacy and safety of blue light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder Cancer: a phase III, comparative, multicenter study. J Urol. 2018;199(5):1158–65.

    Article  PubMed  Google Scholar 

  16. Freifeld Y, Lotan Y. Effect of blue light cystoscopy on contemporary performance of urine cytology. BJU Int. 2019;124(2):251–7.

    Article  PubMed  Google Scholar 

  17. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005;293(7):810–6.

    Article  CAS  PubMed  Google Scholar 

  18. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006;295(3):299–305.

    Article  CAS  PubMed  Google Scholar 

  19. Boman H, Hedelin H, Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low-grade recurrence. J Urol. 2002;167(1):80–3.

    Article  PubMed  Google Scholar 

  20. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol. 1999;162(1):53–7.

    Article  CAS  PubMed  Google Scholar 

  21. Soria F, Droller MJ, Lotan Y, Gontero P, D’Andrea D, Gust KM, et al. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. World J Urol. 2018;36(12):1981–95.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Bell MD, Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, et al. Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study. World J Urol. 2016;34(10):1405–9.

    Article  CAS  PubMed  Google Scholar 

  23. Toma MI, Friedrich MG, Hautmann SH, Jakel KT, Erbersdobler A, Hellstern A, et al. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol. 2004;22(2):145–9.

    Article  PubMed  Google Scholar 

  24. Vriesema JL, Atsma F, Kiemeney LA, Peelen WP, Witjes JA, Schalken JA. Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology. 2001;58(3):367–71.

    Article  CAS  PubMed  Google Scholar 

  25. Pfister C, Chautard D, Devonec M, Perrin P, Chopin D, Rischmann P, et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol. 2003;169(3):921–4.

    Article  PubMed  Google Scholar 

  26. Olsson H, Zackrisson B. ImmunoCyt, a useful method in the follow-up protocol for patients with urinary bladder carcinoma. Scand J Urol Nephrol. 2001;35(4):280–2.

    Article  CAS  PubMed  Google Scholar 

  27. Soria F, D'Andrea D, Pohar K, Shariat SF, Lotan Y. Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice? Curr Opin Urol. 2018;28(6):577–83.

    Article  PubMed  Google Scholar 

  28. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2000;2(3):116–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Dimashkieh H, Wolff DJ, Smith TM, Houser PM, Nietert PJ, Yang J. Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Cancer Cytopathol. 2013;121(10):591–7.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol. 2008;26(6):646–51.

    Article  CAS  PubMed  Google Scholar 

  31. O'Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L, et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol. 2012;188(3):741–7.

    Article  PubMed  Google Scholar 

  32. Lotan Y, O'Sullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urol Oncol. 2017;35(8):531.e15–22.

    Article  Google Scholar 

  33. Kavalieris L, O'Sullivan P, Frampton C, Guilford P, Darling D, Jacobson E, et al. Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study. J Urol. 2017;197(6):1419–26.

    Article  PubMed  Google Scholar 

  34. Pichler R, Fritz J, Tulchiner G, Klinglmair G, Soleiman A, Horninger W, et al. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. BJU Int. 2018;121(1):29–37.

    Article  CAS  PubMed  Google Scholar 

  35. Valenberg F, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, et al. Prospective validation of an mRNA-based urine test for surveillance of patients with bladder cancer. Eur Urol. 2019;75(5):853–60.

    Article  PubMed  Google Scholar 

  36. van Kessel KE, Van Neste L, Lurkin I, Zwarthoff EC, Van Criekinge W. Evaluation of an epigenetic profile for the detection of bladder cancer in patients with hematuria. J Urol. 2016;195(3):601–7.

    Article  PubMed  Google Scholar 

  37. Feber A, Dhami P, Dong L, de Winter P, Tan WS, Martinez-Fernandez M, et al. UroMark-a urinary biomarker assay for the detection of bladder cancer. Clin Epigenetics. 2017;9:8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. D’Andrea D, Soria F, Zehetmayer S, Gust KM, Korn S, Witjes JA, et al. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. BJU Int. 2019;123(6):959–67.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Monteiro-Reis S, Leca L, Almeida M, Antunes L, Monteiro P, Dias PC, et al. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation. Eur J Cancer (Oxford, England: 1990). 2014;50(1):226–33.

    Article  CAS  Google Scholar 

  40. Guo RQ, Xiong GY, Yang KW, Zhang L, He SM, Gong YQ, et al. Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: a prospective, single-center study. Urol Oncol. 2018;36(7):342.e15–23.

    Article  CAS  Google Scholar 

  41. Lerner SP, Goh A. Novel endoscopic diagnosis for bladder cancer. Cancer. 2015;121(2):169–78.

    Article  PubMed  Google Scholar 

  42. Seideman C, Canter D, Kim P, Cordon B, Weizer A, Oliva I, et al. Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence? World J Urol. 2015;33(9):1309–13.

    Article  CAS  PubMed  Google Scholar 

  43. Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq R. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol. 2008;179(6):2164–9.

    Article  PubMed  Google Scholar 

  44. Schlomer BJ, Ho R, Sagalowsky A, Ashfaq R, Lotan Y. Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol. 2010;183(1):62–7.

    Article  PubMed  Google Scholar 

  45. Odisho AY, Berry AB, Ahmad AE, Cooperberg MR, Carroll PR, Konety BR. Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology. Eur Urol. 2013;63(5):936–40.

    Article  PubMed  Google Scholar 

  46. Tabayoyong W, Kamat AM. Current use and promise of urinary markers for urothelial cancer. Curr Urol Rep. 2018;19(12):96.

    Article  PubMed  Google Scholar 

  47. Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ, et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol. 2012;188(6 Suppl):2473–81.

    Article  PubMed  Google Scholar 

  48. Buteau A, Seideman CA, Svatek RS, Youssef RF, Chakrabarti G, Reed G, et al. What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-up. Urol Oncol. 2014;32(2):128–34.

    Article  PubMed  Google Scholar 

  49. Elias K, Svatek RS, Gupta S, Ho R, Lotan Y. High-risk patients with hematuria are not evaluated according to guideline recommendations. Cancer. 2010;116(12):2954–9.

    Article  PubMed  Google Scholar 

  50. Loo RK, Lieberman SF, Slezak JM, Landa HM, Mariani AJ, Nicolaisen G, et al. Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. Mayo Clin Proc. 2013;88(2):129–38.

    Article  PubMed  Google Scholar 

  51. Lotan Y, Capitanio U, Shariat SF, Hutterer GC, Karakiewicz PI. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int. 2009;103(10):1368–74.

    Article  CAS  PubMed  Google Scholar 

  52. Lotan Y, Svatek RS, Krabbe LM, Xylinas E, Klatte T, Shariat SF. Prospective external validation of a bladder cancer detection model. J Urol. 2014;192(5):1343–8.

    Article  PubMed  Google Scholar 

  53. Kipp BR, Karnes RJ, Brankley SM, Harwood AR, Pankratz VS, Sebo TJ, et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol. 2005;173(2):401–4.

    Article  PubMed  Google Scholar 

  54. Mengual L, Marin-Aguilera M, Ribal MJ, Burset M, Villavicencio H, Oliver A, et al. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guerin therapy. Eur Urol. 2007;52(3):752–9.

    Article  PubMed  Google Scholar 

  55. Kamat AM, Dickstein RJ, Messetti F, Anderson R, Pretzsch SM, Gonzalez GN, et al. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer: results of a prospective trial. J Urol. 2012;187(3):862–7.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Kamat AM, Willis DL, Dickstein RJ, Anderson R, Nogueras-Gonzalez G, Katz RL, et al. Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guerin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJU Int. 2016;117(5):754–60.

    Article  PubMed  Google Scholar 

  57. Yates DR, Catto JW. Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours. World J Urol. 2013;31(1):21–9.

    Article  CAS  PubMed  Google Scholar 

  58. Messer J, Shariat SF, Brien JC, Herman MP, Ng CK, Scherr DS, et al. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int. 2011;108:701–5.

    PubMed  Google Scholar 

  59. Gruschwitz T, Gajda M, Enkelmann A, Grimm MO, Wunderlich H, Horstmann M, et al. FISH analysis of washing urine from the upper urinary tract for the detection of urothelial cancers. Int Urol Nephrol. 2014;46(9):1769–74.

    Article  CAS  PubMed  Google Scholar 

  60. Bier S, Hennenlotter J, Esser M, Mohrhardt S, Rausch S, Schwentner C, et al. Performance of urinary markers for detection of upper tract urothelial carcinoma: is upper tract urine more accurate than urine from the bladder? Dis Markers. 2018;2018:5823870.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Lotan Y, Black PC, Caba L, Chang SS, Cookson MS, Daneshmand S, et al. Optimal trial Design for studying urinary markers in bladder cancer: a collaborative review. Eur. Urol. Oncol. 2018;1(3):223–30.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Rashed A. Ghandour, Nirmish Singla & Yair Lotan

Authors
  1. Rashed A. Ghandour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nirmish Singla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yair Lotan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yair Lotan .

Editor information

Editors and Affiliations

  1. Department of Urology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

    Ashish M. Kamat

  2. Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

    Peter C. Black

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ghandour, R.A., Singla, N., Lotan, Y. (2021). Using Urinary Biomarkers in Urothelial Carcinoma of the Bladder and Upper Tracts. In: Kamat, A.M., Black, P.C. (eds) Bladder Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-70646-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-70646-3_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-70645-6

  • Online ISBN: 978-3-030-70646-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation